Search

everythinglearnresearchcommunity

for

Search:↓

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

GLPLS and LPP are variants of lichen planus.

A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.

Intravenous cyclophosphamide effectively treated steroid-resistant lupus cystitis and peritonitis.

New tools and criteria have been developed to better assess and treat pediatric lupus.

Chronic granulomatous disease may be linked to developing systemic lupus erythematosus.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

Low-dose naltrexone helps reduce symptoms and slow down lichen planopilaris without side effects.

Thalidomide improved lupus symptoms but caused nerve damage in some patients.

Single-dose parenteral iron is safe and effective for children with inflammatory bowel disease and iron-deficiency anemia.

Careful monitoring is crucial to prevent JC virus reactivation in lupus patients treated with rituximab.

LustrivaTM improves hair thickness and reduces facial wrinkles safely.

Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.

Genetic screening for NUDT15 polymorphisms is crucial for patients taking azathioprine, especially in Asians.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

Leflunomide successfully treated a rare skin condition in a liver transplant patient.

Skin issues can signal substance use, helping early detection and treatment.

Skin problems like itching, dry skin, and hair loss are more common in hepatitis C patients after interferon treatment, but lichen planus is not linked to the infection.

Lichen spinulosus, usually seen in young people, can rarely occur in adults, as shown by a 52-year-old woman with a rough, bumpy rash.

Consider systemic lupus erythematosus in patients with unexplained intracranial hypertension.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

LALPS causes non-scarring hair loss along the Blaschko line, with unique trichoscopic findings.

A dog with unusual skin lesions near its tail was successfully treated for a rare form of lupus.

Leflunomide with prednisone is effective and well-tolerated for lupus nephritis when cyclophosphamide can't be used.

Certain surgical methods are better than routine incision for hidradenitis suppurativa, topical clindamycin and acitretin are effective treatments, men with HS have a risk of skin cancer, HS patients are more likely to die from heart problems, and specific genetic markers are linked to treatment response.

The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.

COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.

Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.

Linkus cough syrup is effective and safe with no side effects or toxicity in rats.